Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Jun 25, 2019
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how inflammation in the brain develops after a moderate to severe traumatic brain injury (TBI) and how this inflammation might affect the risk of developing post-traumatic epilepsy, which is a type of seizure disorder that can occur after a head injury. Researchers will use a special imaging test called positron emission tomography (PET) scans to look at the brain's inflammation at two different times: two weeks and two months after the injury. By analyzing the results, the study aims to understand the connection between brain inflammation and the likelihood of experiencing seizures later on.
To participate in this study, individuals must be between 18 and 100 years old and have recently suffered an acute TBI. They need to be able to join the study within 72 hours of their injury and have a specific level of consciousness, as measured by a scale called the Glasgow Coma Scale. Patients with certain types of brain injuries, like hemorrhagic contusions, are eligible, while those with a history of epilepsy, severe cognitive issues, or certain injuries may not qualify. If eligible, participants can expect to undergo the PET scans and contribute valuable information that could help improve understanding and treatment of post-traumatic epilepsy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute Traumatic Brain Injury (TBI)
- • Age 18-100 are eligible
- • Glasgow Coma Scale (GCS) 3-13 without continuous sedation at time of enrollment
- • Ability to enroll within 72 hours of injury
- • Hemorrhagic contusional injuries to frontal and/or temporal lobes.
- • Polytrauma including long bone fractures, blunt trauma, abdominal trauma or similar will be allowed
- • Penetrating TBI if continuous electroencephalography (cEEG) is feasible and survival for 2 years is feasible, recognizing that MRI may not be feasible with some forms of penetrating trauma
- Exclusion Criteria:
- • Low-affinity TSPO binding profile
- • Ages 17 years or younger
- • Patients with diffuse axonal injury in the absence of hemorrhagic contusions or skull fracture, and isolated epidural hemorrhages that improve after evacuation
- • No planned continuous EEG monitoring during injury day 1-7
- • Inability to undergo MRI at 14 days (± 4 days) due to bullet, metal implant, or pacemaker
- • Pregnancy
- • Pre-existing Neurodegenerative Disorders
- • Pre-existing epilepsy/seizure disorder
- • Pre-existing dementia
- • Isolated anoxic brain injury
- • Incarceration present or pending
- • Devastating cervical spine injury
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials